A phase II study of hepatic arterial infusion with floxuridine and dexamethasone in combination with intravenous bevacizumab (a monoclonal antibody to vascular endothelial growth factor-A), in patients with unresectable primary hepatic malignancy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Dexamethasone (Primary) ; Floxuridine (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 10 Aug 2021 Biomarkers information updated
- 14 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jul 2007 Status changed from initiated to recruiting.